Treatment of Anemia in Chronic Kidney Failure ESKD patients Treatment of Chemotherapy induced Anemia in Cancer patients Treatment of Anemia in Zidovudine-treated HIV-infected patients, Perioperative Surgery Patients needing Allogenic Blood Transfusion Adult Surgery Patients in an Autologous Pre-Donation Programme.
Hepatitis B vaccine is indicated for active immunisation against hepatitis B infection in subjects considered at risk of exposure to HBV-positive material. 10 mcg dose (in 0.5 ml suspension) is recommended for neonates, infants, children and adolescents upto 19 years of age.20 mcg dose (1.0 ml suspension) is recommended for adults aged 20 years and above.
For active immunization against Measles Administered to children and adolescents who have been vaccinated before or have had measles infection earlier, Each single human dose when reconstituted in a volume of 0.5ml contains not less than 1000 CCID50 of live Measles virus particles.
0.05 ml, Intradermal for Infants under one year of age, 0.1 ml, Intradermal for children over one year of age and adult.For the prevention of Tuberculosis, BCG is preferably given at birth to provide protection in the early years when infection can often lead to diseases such as miliary tuberculosis or tubercular meningitis.Infants may receive the vaccine soon after birth or later, but preferably before exposure to persons with active tuberculosis.
For the immunization of infants, children and adults of all ages For the people at greater risk at work eg. gardeners, athletes, farmers, laboratory staff etc. For women of childbearing age and pregnant women to prevent neonatal tetanus.First dose at the confirmation of pregnancy Second dose after four weeks of the first dose of tetanus toxoid vaccine.
For active immunization against rubellaFor immunization of adolescents and adult males for preventing or controlling outbreaks of rubellaFor immunization of susceptible non-pregnant females of childbof 0.5 ml contains: Not less than 1000 CCID50 of live rubella virus particles
For active immunization against invasive meningococcal disease caused by meningococcus group A only.Children from 12 months of age, adolescents and adults up to 29 years of age should receive a single 0.5 ml dose.
Poliomyelitis virus type 1, Mahoney strain 40 D antigen unitsPoliomyelitis virus type 2, MEF-I strain 8 D antigen unitsPoliomyelitis virus type 3, Saukett strain 32 D antigen unitsPreservative : 2-phenoxyethanol 2.5 mg Formaldehyde 12.5 mcg* Cultivated on Vero Cells
Pediatric dose vaccine: 10 mcg dose (in 0.5 ml suspension) is recommended for neonates, infants, children and adolescents upto 19 years of age.Adult dose vaccine: 20 mcg dose (1.0 ml suspension) is recommended for adults aged 20 years and above
First dose of MMR given in children - 12 months of age to10 years of age.Second dose of MMR is advocated any time before the age of 6 years (elementary school entry 4-6 years) and thereafter Measles and Rubella vaccine is recommended.For active immunization against Measles and Rubella in infants, children, adolescents and young adults at risk.
Hadapsar, pune, Maharashtra 